Skip to main navigation

Overview
Newsroom
Events & Presentations
- Events
- Presentations
Financials
- SEC Filings
- Annual Reports
Stock Information
Corporate Governance

Top bar

Biogen.com Information Request Sign up for Alerts Search

Presentations

Earnings Presentations

Q1 2021 Biogen Earnings Presentation

Apr 22, 2021

Q4 and Full Year 2020 Biogen Earnings Presentation

Feb 03, 2021

Q3 2020 Biogen Earnings Presentation

Oct 21, 2020

Q2 2020 Biogen Earnings Presentation

Jul 22, 2020

Q1 2020 Biogen Earnings Presentation

Apr 22, 2020

Q4 2019 Biogen Earnings Presentation

Jan 30, 2020

Conference and Other Investor Presentations

Biogen ADUHELM Launch

Jun 08, 2021

J.P. Morgan 39th Annual Healthcare Conference

Jan 11, 2021

Aducanumab Update Presentation

Oct 22, 2019

Biogen ALS & R&D Portfolio Webcast Presentation

Jun 05, 2019

Biogen Planned Acquisition of Nightstar Therapeutics

Mar 04, 2019

Biogen MS & R&D Webcast Presentation

Dec 12, 2018

Biogen on R&D Progress Targeting Stroke

Jun 28, 2018

Medical and Scientific Conference Presentations

Aducanumab EMBARK study design audio presentation at AAN 2021

Apr 17, 2021

Aducanumab EMBARK study design poster at AAN 2021

Apr 17, 2021

Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD

Mar 13, 2021

Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD

Mar 13, 2021

Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD

Mar 10, 2021

Aducanumab data review with Global Alzheimer's Platform Foundation

Feb 23, 2021

Aducanumab data review and Q&A with Alzheimer's Disease International

Jan 14, 2021

Aducanumab EMBARK study design at CTAD 2020

Nov 04, 2020

Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation)

Sep 23, 2020

Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation)

Sep 19, 2020

A Biogen Perspective on Drug Development for Neurological Diseases: The Example of Alzheimer’s Disease

Aug 31, 2020

Aducanumab Phase 3 Topline Results at AAIC (encore virtual presentation)

Jul 29, 2020

Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation)

May 18, 2020

Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation)

Apr 02, 2020

Aducanumab Phase 3 Topline Results at CTAD

Dec 05, 2019

Safety, PK, PD, and Exploratory Efficacy in Single and Multiple Dose Study of a SOD1 Antisense Oligonucleotide (BIIB067) Administered to Participants With ALS

May 07, 2019

CTAD Oral Presentation: Aducanumab Titration Dosing Regimen: 36-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease

Oct 26, 2018

CTAD Keynote: What Have We Learned from Aducanumab?

Oct 25, 2018

Aducanumab 48-Month Analyses from PRIME, a Phase 1b Study in Patients with Early Alzheimer’s Disease

Oct 24, 2018

Cumulative Aducanumab Safety Data from PRIME: A Randomized, Double-blind, Placebo-controlled, Phase 1b Study

Oct 24, 2018

24-Month Analysis of APOE ε4 Carriers in PRIME, a Randomized Phase 1B Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab

Jul 22, 2018

24-Month Analysis of Change From Baseline In Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, A Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab

Jul 22, 2018

Aducanumab Titration Dosing Regimen: 24-Month Interim Analysis from PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease

Apr 22, 2018

Aducanumab 36-Month Data From PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease

Apr 22, 2018

The Importance of Early Identification and Treatment of Alzheimer’s Disease

Mar 15, 2018

NUSINERSEN CHERISH Final Results (Poster & Presentation) Ph3 AAN 2017

Apr 25, 2017

Source

AAN, April 25, 2017

NUSINERSEN NURTURE Interim Results (Presentation) Ph3 AAN 2017

Apr 25, 2017

Source

AAN, April 25, 2017

NUSINERSEN ENDEAR Final Results (Presentation) Ph3 AAN 2017

Apr 24, 2017

Source

AAN, April 24, 2017

Annual Stockholder Presentation

Biogen Annual Stockholder Presentation 2021

June 2, 2021

Hemophilia Spin-off Presentations

Bioverativ (BIVV) Analyst Day Presentation

January 6, 2017

Hemophilia Spin-off Presentation

May 3, 2016

Tools

Stockholder Communications

Footer Links

Investors
Careers
News Releases
Our Stories
Receive Our Updates
Contact Us

Follow us:

Legal

Community Guidelines
Cookie Policy
Forward-Looking Statement
Notice to CA Residents
Privacy Policy
Terms & Conditions
© 2021 Biogen

Facebook
Twitter
LinkedIn
Google+